Ricevo su appuntamento (concordato via e-mail elisabetta.rovida@unifi.it) generalmente il lunedì alle 12.

La Dott.ssa Elisabetta Rovida ha conseguito il titolo di Laurea in Scienze Biologiche presso l'Università di Firenze, Italia, con il massimo dei voti e lode nel 1995. Nel 2001 ha conseguito il titolo di Dottore di Ricerca in Patologia Sperimentale presso l'Università di Firenze, sotto la supervisione del Prof. Massimo Olivotto, lavorando in parte all'Università di Vienna, in Austria, nel laboratorio della Prof. Manuela Baccarini. Ha effettuato 10 anni di formazione post-dottorato, 5 dei quali supportati da borse di ricerca finanziate dall'Associazione Italiana per la Ricerca sul Cancro (AIRC / FIRC), nell’ambito della ricerca di base sul cancro sotto la supervisione del Dott. Persio Dello Sbarba, Università di Firenze. Nel 2011 ha vinto un concorso per Ricercatore Universitario a tempo determinato presso il Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università di Firenze, Italia, dove lavora tuttora come Ricercatore a tempo determinato finalizzato alla posizione di Professore Associato. Dal 2021 è Professore Associato. È responsabile della ricerca o collaboratore in diversi progetti finanziati da agenzie nazionali o internazionali. È revisore di diverse riviste internazionali e agenzie di finanziamento internazionali. È membro di diverse associazioni scientifiche. Gli interessi scientifici sono il ruolo della fosforilazione delle proteine ​​in diversi processi biologici come la sopravvivenza, la proliferazione, l'apoptosi, l'adesione e la motilità, nelle cellule normali o neoplastiche. Principali risultati scientifici riguardano la delucidazione dei meccanismi di segnalazione da parte del recettore per il Colony-Stimulating Factor 1, nonché il ruolo delle Mitogen-Activated Protein Kinases, in particolare ERK5, nelle cellule normali e neoplastiche. Ha pubblicato più di 70 articoli peer reviewed e dozzine di abstract di congressi a cui ha partecipato sulle basi molecolari delle malattie, in particolare il cancro. Ha supervisionato il lavoro di tesi di molti studenti di Scienze Biologiche, Biotecnologie Mediche e Biotecnologie mediche e farmaceutiche e del Dottorato in Genetica, Oncologia e Clinica Medica (GenOMeC). E.R. è anche titolare dell'insegnamento di Patologia Generale in numerosi corsi di studio della Scuola di Scienze della Salute Umana dell'Università di Firenze.

Identificazione di meccanismi molecolari responsabili di una sostenuta proliferazione cellulare e di una ridotta sensibilità ai fattori antiproliferativi nelle cellule tumorali con particolare attenzione al coinvolgimento nei suddetti processi biologici del recettore per il Colony-Stimulating Factor-1 (CSF-1R) e delle Mitogen-Activated Protein Kinases (MAPK), ERK5 in particolare.

Identificazione di meccanismi di resistenza alle terapie molecolari dirette alle MAPK nei tumori solidi e a BCR/ABL nella leucemia mieloide cronica.

Dr. Elisabetta Rovida received a Bachelor of Science degree and a Master of Science degree in Biological Sciences from Florence University, Italy, with honors in 1995. In 2001 she completed a PhD in Experimental Pathology at Florence University, Italy, under the supervision of Prof Massimo Olivotto, working in part at Vienna University, Austria, in the laboratory of Prof. Manuela Baccarini. She underwent 10 years of postdoctoral training, 5 of which were supported by fellowships funded by the Italian Association for Cancer Research (AIRC/FIRC), in basic cancer research under the supervision of Dr. Persio Dello Sbarba, Florence University. In 2011 she was appointed as Assistant Professor at the Department of Experimental and Clinical Biomedical Sciences, Florence University, Italy, where she is a tenure-track assistant professor. She is Principal Investigator and co-investigator in several funded projects from National or International agencies. She is a reviewer of several international journals as well as international funding agencies. She is a member of several scientific associations. Scientific interests are the role of protein phosphorylation in different biological processes such as survival, proliferation, apoptosis, adhesion and motility, in normal or neoplastic cells. Main scientific achievements deal with elucidating mechanisms of signaling by the Colony-Stimulating Factor 1 Receptor as well as the role of Mitogen-Activated Protein Kinases, ERK5 in particular, in normal and neoplastic cells. She has published more than 70 peer-reviewed articles and dozens of meeting abstracts on the molecular basis of diseases, particularly cancer.She supervised the thesis work of several Biological Sciences, Medical Biotechnologies, and the PhD program in Genetics, Oncology and Clinical Medicine. E.R. is also in charge of teaching General Pathology in many courses at the School of Human Health Sciences of Florence University.

 EDUCATION

 2001, March 3rd PhD in Experimental Pathology, University of Florence, Italy.

 1995, April 26th Degree in Biological Sciences, University of Florence, Italy, cum laude.

PROFESSIONAL EXPERIENCES

01/12/2021-today Associate Professor at the Department of Experimental Pathology and Oncology, University of Florence, Italy.

 01/12/2018-30/11/2021 Assistant Professor with tenure track to Associate Professor at the Department of Experimental Pathology and Oncology, University of Florence, Italy.

 01/09/2016-30/11/2018 Assistant Professor (fixed term) at the Department of Experimental Pathology and Oncology, University of Florence, Italy.

01/01/2014-31/08/2016 Senior Research Scientist at the Department of Experimental Pathology and Oncology, University of Florence, Italy.

01/01/2011-31/12/2013 Assistant Professor (fixed term) at the Department of Experimental Pathology and Oncology, University of Florence, Italy. Project title: "New therapeutic targets from the biology of the BCR-ABL oncogene" funded by Ministero della Salute (Ricerca finalizzata) - Regione Toscana.

22/02/2010-31/12/2010 Post-doc (Collaboratore coordinato e continuativo) at the Department of Experimental Pathology and Oncology, University of Florence, Italy. Project title: "Characterisation and drug sensitivity of BCR/Abl-independent, Imatinib-resistant CML cells selected in hypoxia" funded by the "Associazione Italiana per la Ricerca sul cancro (AIRC)".

01/01/2009-31/12/2009 Post-doc (Assegnista di ricerca) at the Department of Experimental Pathology and Oncology, University of Florence, Italy. Project title: "Inhibition of BCR/Abl expression and induction of alternative anti-apoptotic mechanisms in hypoxia-adapted / Imatinib-insensitive CML stem cells" funded by the "Istituto Toscano Tumori (ITT)".

01/03/2007-31/12/2008 Post-doc (Borsista) at the Department of Experimental Pathology and Oncology, University of Florence, Italy. Project title: "Role of the microenvironment and of epigenetic events in theregulation of the leukemic stem cell compartment" funded fy the "Fondazione Italiana per la Ricerca sul Cancro (FIRC)".

 01/03/2004-28/02/2007 Post-doc (Assegnista di ricerca) at the Department of Experimental Pathology and Oncology, University of Florence, Italy. Project title: "Role of hypoxia in the selection andmaintenance of normal and neoplastic haematopoietic stem cells" funded by "Istituto Superiore di Sanità (ISS), Programma nazionale Cellule staminali".

02/01/2004-28/02/2004 Post-doc (Borsista) at the Department of Experimental Pathology and Oncology, University of Florence, Italy. Project title: "Charachterization of the phenotype of the chronic myeloid leukemia cell line in response to deep hypoxia" funded by "Ente Cassa di Risparmio di Firenze".

01/01/2001-31/12/2003 Post-doc (Borsista) at the Department of Experimental Pathology and Oncology, University of Florence, Italy. Project title: "Role of the Fes oncogene in the proliferation, differentiationand in the adhesion of normal and neoplastic myeloid cells" funded fy the "Fondazione Italiana per la Ricerca sul Cancro (FIRC)"

2001, March 3rd PhD in Experimental Pathology, University of Florence. Thesis Title: "L'oncogene fes e la fosfotirosino-fosfatasi citosolica a basso peso molecolare interferiscono con la proliferazione e l'adesione cellulare". Tutor Prof. Massimo Olivotto.

05/03/2000-05/06/2000 Visiting PhD student at the laboratory of Professor Manuela Baccarini, Institute of Microbiology and Genetics, University of Vienna, Austria. Investigation of the role of the MAPK proto-oncogene tpl-2 in macrophage proliferation.

1996-2000 PhD student at the Department of Experimental Pathology and Oncology, University of Florence, Italy. Supervisor, Dr Persio Dello Sbarba.

1995, April 26th Degree in Biological Sciences, University of Florence, 110/110 cum laude. Thesis title: La modulazione del recettore per il Macrophage Colony-Stimulating Factor da parte dell'Interleuchina-2 èmediata dalla Proteinchinasi-C e dalla Fosfolipasi-C". Tutor Prof. Massimo Olivotto.

July 1993-April 1995 Research intern at the Department of Experimental Pathology and Oncology, University of Florence, Italy. Supervisor, Dr Persio Dello Sbarba.

PAPERS PUBLISHED IN PEER-REVIEWED JOURNALS indexed in Scopus/Isi with Impact Factor (citation score from Google Scholar; *co-/corresponding author, ^§co-first/co-last author; bold: active author).

1. Rovida E, Tusa I, Lewinska M, Andersen JB, Lottini T, Arcangeli A, Taddei ML, Pranzini E, Madiai S, Sacco E, Rota S, Trapani A, Agrimi G, Ramazzotti M, Ostano P, Peraldo Neia C, Parri M, Carli F, Sabatini S, Gastaldelli A, Marra F, Raggi C. Altered fatty acid metabolism rewires cholangiocarcinoma stemness features. JHEPR.Available online 6 August 2024, 101182 doi.org/10.1016/j.jhepr.2024.101182.IF2023 9.5.
2. Filippelli A, Ciccone V, Del Gaudio C, Simonis V, Frosini M, Tusa I, Menconi A, Rovida E^§, Donnini S. ERK5 mediates pro-tumorigenic phenotype in non-small lung cancer cells induced by PGE2. Biochim Biophys Acta Mol Cell Res. 2024 1871(7):119810. doi: 10.1016/j.bbamcr.2024.119810. IF2023 4.6.
3. Rovida E. Importin subunit beta-1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation. Mol Oncol. 2024 doi: 10.1002/1878-0261.13674. PMID: 38965815. IF2023 5.00.
4. Rovida E. Latent-Transforming Growth Factor β-Binding Protein 1/Transforming Growth Factor β1 Complex Drives Antitumoral Effects upon ERK5 Targeting in Melanoma. Am J Pathol. 2024 194(8):1581-1591. doi: 10.1016/j.ajpath.2024.03.015.  IF2023 4.7.
5. Rovida E^§, Donati C. Sphingosine 1-phosphate elicits a ROS-mediated proinflammatory response in human endometrial stromal cells via ERK5 activation. FASEB J. 2023 37(8):e23061. doi: 10.1096/fj.202300323R. PMID: 37389926.IF2022 4.8.
6. Tusa I, Menconi A, Tubita A, Rovida E. Pathophysiological impact of the MEK5/ERK5 pathway in oxidative stress. Cells 2023, 12, 1154. doi: 10.3390/cells12081154. PMID: 37190064.  IF2021 7.7.
7. Maglie R, De Almeida CV, Baffa ME, Bianchi B, Caproni M, Di Zenzo G, Li X, Hirako Y, Hashimoto T, Tusa I, Lulli M, Rovida E^§, Antiga E. Anti-β4 integrin autoantibodies in patients with mucous membrane pemphigoid: a retrospective analysis from a tertiary centre in Italy. J Eur Acad Dermatol Venereol. 2023 37(2):e249-e251. doi: 10.1111/jdv.18617. PMID: 36166640. IF2021 9.3.
8. Rovida E, Chiariello M. MAPK15 protects from oxidative stress-dependent cellular senescence by inducing the mitophagic process. Aging Cell. 2022 21(7):e13620. doi: 10.1111/acel.13620. PMID: 35642724. IF2020 9.2.
9. Rovida E, Tusa I. Targeting MAPK in Cancer 2.0. Int J Mol Sci. 2022 23(10):5702. doi: 10.3390/ijms23105702. PMID: 35628511; PMCID: PMC9143559. IF2020 5.9.
10. Rovida E^§, Dello Sbarba P. Lactate maintains BCR/Abl expression and signaling in Chronic Myeloid Leukemia cells under nutrient restriction. Oncol Res. 2022 29(1):33-46. doi: 10.3727/096504022X16442289212164. IF2020 4.9.
11. Rovida E, Piccinni MP, Lombardelli L, Logiodice F, Rombouts K, Petta S, Marra F. Macrophage MerTK promotes a profibrogenic cross-talk with hepatic stellate cells via soluble mediators. JHEP Rep. 2022 4(4):100444. doi: 10.1016/j.jhepr.2022.100444. IF2021 9.9.
12. Rovida E. Inhibition of ERK5 elicits cellular senescence in melanoma via the cyclin-dependent kinase inhibitor p21. Cancer Res. 2022 82(3):447-457. doi: 10.1158/0008-5472.CAN-21-0993. IF2020 12.7.
13. Rovida E. The Hedgehog-GLI pathway regulates MEK5-ERK5 expression and activation in melanoma cells. Int. J. Mol. Sci. 2021 22(20):11259. doi: 10.3390/ijms222011259. IF2020 5.9.
14. Foglia B, Sutti S, Cannito S, Rosso C, Maggiora M, Autelli R, Novo E, Bocca C, Villano G, Ramavath N, Younes R, Tusa I, Rovida E, Pontisso P, Bugianesi E, Albano E, Parola M. Hepatocyte-specific deletion of HIF2α prevents NASH-related liver carcinogenesis by decreasing cancer cell proliferation. Cell Mol Gastroenterol Hepatol 2021 13(2):459-482. doi: 10.1016/j.jcmgh.2021.10.002. IF2020 9.2.
15. Rovida E^§, Dello Sbarba P. Glutamine Availability Controls BCR/Abl Protein Expression and Functional Phenotype of Chronic Myeloid Leukemia Cells Endowed with Stem/Progenitor Cell Potential. Cancers. 2021, 13(17), 4372.  IF2020 6.6.
16. Rovida E^§, Marra F. ¶Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells. Hepatology 2021 74(4):2007-2020. IF2020 17.4.
17. Rovida E. Playing the Whack-a-mole Game: ERK5 Activation Emerges among the Resistance Mechanisms to RAF-MEK1/2-ERK1/2-targeted Therapy. Front. Cell Dev. Biol., 2021 Mar 11;9:647311. doi: 10.3389/fcell.2021.647311. IF2019 5.2.
18. Rovida E, Del Rosso M, Fibbi G, Laurenzana A. Enhanced Antitumoral Activity and Photoacoustic Imaging Properties of AuNP-Enriched Endothelial Colony Forming Cells on Melanoma. Adv Sci (Weinh). 2020 8(4):2001175. doi: 10.1002/advs.202001175. IF2019 15.8.
19. Rovida E. In vitro comparison of the effects of imatinib and ponatinib on Chronic Myeloid Leukemia progenitor/stem cell features. Target Oncol. 2020.15(5):659-671. IF2019 4.0.
20. Rovida E. Beyond Kinase Activity: ERK5 Nucleo-Cytoplasmic Shuttling as a Novel Target for Anticancer Therapy. Int. J. Mol. Sci. 2020, 21(3), 938. IF2019 4.6.
21. Rovida E, Lewinska M, Andersen JB, Borgo C, Salvi M, Ottaviani D, Ruzzene M, Marra F. The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells. Oncogenesis. 2019 8(11):61. doi:10.1038/s41389-019-0171-x. IF2018 6.0.
22. Rovida E, Peraldo-Neia C, Olaizola P, Banales JM, Gerussi A, Elvevi A, Droz Dit Busset M, Bhoori S, Mazzaferro V, Alpini G, Marra F, Invernizzi P. Antitumor Activity of a Novel Fibroblast Growth Factor Receptor (FGFR) Inhibitor for Intrahepatic Cholangiocarcinoma. Am J Pathol. 2019 189(10):2090-2101. doi: 10.1016/j.ajpath.2019.06.007.. IF2018 3.8.
23. Rovida E, Navari N, Di Matteo S, Alvaro D, Banales JM, Rodrigues P, Raschioni C, Donadon M, Di Tommaso L, Marra F. CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. Biochim Biophys Acta Mol Basis Dis. 2019 1865(9):2246-2256. doi: 10.1016/j.bbadis.2019.04.020. IF2018 4.4.
24. Rovida E. Impact of ERK5 on the Hallmarks of Cancer. Int J Mol Sci. 2019 20(6). pii: E1426. doi: 10.3390/ijms20061426. Review. IF2018 4.2.
25. Rovida E^§, Dello Sbarba P. Targeting the Extracellular Signal-RegulatedKinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells. Stem Cell Reports. 2018 11(4):929-943. doi: 10.1016/j.stemcr.2018.08.016. IF2017 7.3.
26. Rovida E. ERK5 is activated by oncogenic BRAF and promotes melanoma growth. Oncogene. 2018 37(19):2601-2614. doi:10.1038/s41388-018-0164-9. IF2017 7.5.
27. Rovida E^§, Li S, Dello Sbarba P. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood. 2017 130(5):655-665. IF2016 13.2.
28. Rovida E, Lulli M, Dello Sbarba P. The Leukemic Stem Cell Niche: Adaptation to “Hypoxia” versus Oncogene Addiction. Stem Cells Int. 2017;2017:4979474. doi: 10.1155/2017/4979474.IF2016 3.5.
29. Rovida E, Olivotto M, Dello Sbarba P. Low-dose methotrexate enhances cycling of highly anaplastic cancer cells. Cell Cycle. 2017 16(3):280-285. doi: 10.1080/15384101.2016.1252883. IF2015 4.0.
30. Rovida E, Dello Sbarba P. Chronic Myeloid Leukemia and Hepatoblastoma: Two Cancer Models to Link Metabolism to Stem Cells. Front Oncol. 2016 6:95. doi: 10.3389/fonc.2016.00095. Review. PubMed PMID: 27148487.IF2017 4.4. 
31. Rovida E^§, Dello Sbarba P. Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction. Oncotarget. 2016 7(51):84810-84825. doi: 10.18632/oncotarget.13319. IF2015 5.1.
32. Rovida E. Fibronectin induces macrophage migration through a SFK-FAK/CSF-1R pathway. Cell Adh Migr. 2017 11(4):327-337. doi: 10.1080/19336918.2016.1221566. IF2015 3.3.
33. Rovida E, Dello Sbarba P, Olivotto M, Marzi I. The complex metabolic network gearing the G1/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents. Oncotarget. 2015 6(31):31985-96. doi: 10.18632/oncotarget.5155. IF2015 5.1.
34. Rovida E^§, Dello Sbarba P. Salarin C inhibits maintenance of hypoxia-selected Chronic Myeloid Leukemia progenitor cells. Cell Cycle. 2015 14(19):3146-54. IF2015 4.0.
35. Rovida E, Stecca B. Mitogen-Activated Protein Kinases and Hedgehog-GLI signaling in cancer: a crosstalk providing therapeutic opportunities? Semin Cancer Biol. 2015 35:154-67. doi: 10.1016/j.semcancer.2015.08.003. Review. IF2015 10.
36. Rovida E. Prostaglandin E2 trans-activates the Colony-Stimulating Factor-1 (CSF-1) receptor and synergizes with CSF-1 in the induction of macrophage migration via the mitogen-activated protein kinase ERK1/2. FASEB J. 2015 29(6):2545-54. IF2015 5.3.
37. Rovida E, Del Rosso M, Margheri F. Lipid rafts: integrated platforms for vascular organization offering therapeutic opportunities. Cell Mol Life Sci. 2015 72(8):1537-57. IF2015 5.7.
38. Rovida E, Autelli R, Smedile A, Cillo U, Pontisso P, Parola M. Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells. Oncotarget. 2015 6(4):2206-2221. IF2015 5.1.
39. Rovida E^§, Di Maira G, Tusa I, Cannito S, Paternostro C, Navari N, Vivoli E, Deng X, Gray NS, Esparís-Ogando A, David E, Pandiella A, Dello Sbarba P, Parola M, Marra F. The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. Gut. 2015 64(9):1454-65. doi:10.1136/gutjnl-2014-306761. Epub 2014 Sep 2. IF2015 14.9.
40. Rovida E, Peppicelli S, Bono S, Bianchini F, Tusa I, Cheloni G, Marzi I, Cipolleschi MG, Calorini L, Dello Sbarba P. The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy. Cell cycle. 2014 13(20):3169-3175. IF2015 4.0.
41. Rovida E^§, Dello Sbarba P. Possible mechanisms and function of nuclear trafficking of the colony-stimulating factor-1 receptor. Cell Mol Life Sci. 2014 71(19):3627-31. IF2015 5.7.
42. Cipolleschi MG, Marzi I, Santini R, Fredducci D, Vinci MC, D’Amico M, Rovida E, Stivarou T, Torre E, Dello Sbarba P, Stecca B, Olivotto M. Hypoxia-resistant profile implies vulnerability of cancer stem cells to physiological agents which suggests new therapeutic targets. Cell Cycle. 2014 13(2):268-78. doi: 10.4161/cc.27031. IF2015 4.0.
43. Barbetti V, Morandi A, Tusa I, Digiacomo G, Riverso M, Marzi I, Cipolleschi MG, Bessi S, Giannini A, Di Leo A, Dello Sbarba P, Rovida E. Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells. Oncogene. 2014 3(34):4359-64. doi: 10.1038/onc.2013.542. Epub 2013 Dec 23. IF2015 7.9.
44. Barbetti V, Tusa I, Cipolleschi MG, Rovida E^§, Dello Sbarba P. AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia Cell Death Dis. 2013 Mar 14;4:e536. doi: 10.1038/cddis.2013.49. IF2015 5.4.
45. Barbetti V, Gozzini A, Cheloni G, Marzi I, Fabiani E, Santini V, Dello Sbarba P, Rovida E. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO positive leukemia cells. Epigenetics. 2013 8(2):210-9. doi: 10.4161/epi.23538. IF2015 4.8.
46. Rovida E, Dello Sbarba P. The Culture-Repopulating Ability assays and incubation in low oxygen: a simple way to test drugs on leukaemia stem or progenitor cells. Curr. Pharm. Des. 2013 19(30):5374-83. IF2015 3.1.
47. Marzi I, Cipolleschi MG, D'Amico M, Stivarou D, Rovida E, Vinci MC, Pandolfi S, Dello Sbarba P, Stecca B, Olivotto M. The involvement of a Nanog, Klf4 and c-Myc transcriptional circuitry in the intertwining between neoplastic progression and reprogramming. Cell Cycle. 2013 12(2):353-64. doi: 10.4161/cc.23200. IF2015 4.0.
48. Morandi A, Barbetti V, Riverso M, Dello Sbarba P, Rovida E. The Colony-Stimulating Factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines. Plos One. 2011;6(11):e27450. doi: 10.1371/journal.pone.0027450. Epub 2011 Nov 9. IF2015 3.1.
49. Tanturli M, Giuntoli S, Barbetti V, Rovida E, Dello Sbarba P. Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia. PLoS One. 2011 2011 6(2):e17008. doi: 10.1371/journal.pone.0017008. IF2015 3.1.
50. Giuntoli S, Tanturli M, Di Gesualdo F, Barbetti V, Rovida E, Dello Sbarba P. Glucose availability in hypoxia regulates the selection of Chronic Myeloid Leukaemia progenitor subsets with different resistance to Imatinib-mesylate. Haematologica. 2011 96(2):204-12. doi: 10.3324/haematol.2010.029082. IF2015 6.7.
51. Rovida E, Dello Sbarba P. p38 and cancer: yang gets yin. Cancer Biol Ther. 2008 7(8):1241-2. IF2015 2.9.
52. Rovida E^§, Spinelli E, Sdelci S, Barbetti V, Morandi A, Giuntoli S, Dello Sbarba P. ERK5/BMK1 is indispensable for optimal colony-stimulating factor 1 (CSF-1)-induced proliferation in macrophages in a Src-dependent fashion. J Immunol. 2008 180(6):4166-72. IF2015 5.
53. Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G, Mascagni P, Lübbert M, Dello Sbarba P, Santini V. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene. 2008 27(12):1767-78. IF2015 7.9.
54. Rovida E, Navari N, Caligiuri A, Dello Sbarba P, Marra F. ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells. J Hepatol. 2008 48(1):107-15. IF2015 10.6.
55. Giuntoli S, Rovida E, Gozzini A, Barbetti V, Cipolleschi MG, Olivotto M, Dello Sbarba P. Severe hypoxia defines heterogeneity and selects highly immature progenitors within clonal erythroleukemia cells. Stem Cells. 2007 25(5):1119-25. IF2015 5.9.
56. Rovida E, Gozzini A, Barbetti V, Giuntoli S, Santini V, Dello Sbarba. The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) AML cells. Brit J Haematol 2006 135:653-9. IF2015 5.8.
57. Giuntoli S, Rovida E, Barbetti V, Cipolleschi MG, Olivotto M, Dello Sbarba P. Hypoxia suppresses BCR/Abl and selects Imatinib-insensitive progenitors within clonal CML population. Leukemia 2006 20;1291-3. IF2015 12.1.
58. Rovida E, Lugli B, Barbetti V, Giuntoli S, Olivotto M, Dello Sbarba P. FAK is redistributed to focal complexes and mediates cell spreading in macrophages in response to M-CSF. Biol Chem.2005 386(9):919-29. IF2015 2.7.
59. Gozzini A, Rovida E^§, Dello Sbarba P, Galimberti S, Santini V. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. Cancer Res. 2003 63:8955-61. IF2015 8.6.
60. Chiarugi A, Rovida E, Dello Sbarba P, Moroni F. Tryptophan availability selectively limits NO-synthase induction in macrophages. J Leukocyte Biol. 2003 73:172-7. IF2015 4.2.
61. Rigacci S, Rovida E, Dello Sbarba P, Berti A. Low M(r) phosphotyrosine protein phosphatase associates and dephosphorylates p125 focal adhesion kinase, interfering with cell motility and spreading. J Biol Chem. 2002 277:41631-6. IF2015 4.3.
62. Rovida E, Baccarini M, Olivotto M, Dello Sbarba P. Opposite effects of different doses of MCSF on ERK phosphorylation and cell proliferation in macrophages. Oncogene. 2002 21:3670-6. IF2015 7.9.
63. Rovida E. Transmodulation of cell surface regulatory molecules via ectodomain shedding. Biol Chem. 2002 383:69-83. Review. IF2015 2.7.
64. Rovida E, Paccagnini A, Del Rosso M, Peschon J, Dello Sbarba P. TNF-alpha-converting enzyme cleaves the macrophage colony-stimulating factor receptor in macrophages undergoing activation. J Immunol. 2001 166:1583-9. IF2015 5.
65. Rovida E, Marra F, Baccarini M, Dello Sbarba P. Constitutive activation of the MAPK pathway mediates v-fes-induced mitogenesis in murine macrophages. Blood. 2000 95:3959-63. IF2015 11.8.
66. Rovida E, Ivanovic Z, Praloran V, Olivotto M, Dello Sbarba P. The expansion of murine bone marrow cells preincubated in hypoxia as an in vitro indicator of their marrow-repopulating ability. Leukemia. 2000 14:735-9. IF2015 12.1.
67. Rovida E, Milenkovic P, Praloran V, Dello Sbarba P. Incubation of murine bone marrow cells in hypoxia ensures the maintenance of marrow-repopulating ability together with the expansion of committed progenitors. Brit J Haematol. 2000 108(2):424-9. IF2015 5.8.
68. Rovida E, Bagnoli S, Dello Sbarba P, Berti A. Low M(r) phosphotyrosine protein phosphatase activity on fibroblast growth factor receptor is not associated with enzyme translocation. FEBS Lett. 1999 459(2):191-4. IF2015 3.5.
69. Rovida E, Rigacci S, Paccagnini A, Dello Sbarba P, Berti A. The low-molecular-weight phosphotyrosine protein phosphatase, when overexpressed, reduces the mitogenic response to macrophage colony-stimulating factor and tyrosine phosphorylation of its receptor. Biochem Bioph Res Comm. 1998 18;253(2):300-4. IF2015 2.4.
70. Rovida E, Caciagli B, Nencioni L, Labardi D, Paccagnini A, Savini L, Cipolleschi MG. Interleukin-4 rapidly down-modulates the macrophage colony-stimulating factor receptor in murine macrophages. J Leukocyte Biol. 1996 60(5):644-650. IF2015 4.2.
71. Dello Sbarba P, Nencioni L, Labardi D, Rovida E, Caciagli B, Cipolleschi MG. Interleukin 2 down-modulates the macrophage colony-stimulating factor receptor in murine macrophages. Cytokine. 1996 8(6):488-494. IF2015 2.9.

 PAPERS PUBLISHED IN OTHER INTERNATIONAL PEER-REVIEWED JOURNALS

49 peer reviewed publications in scientific journals

Total impact factor (IF 2015-2017): 273

Average impact factor          : 6

First/last/Corresponding author (27/45 papers) IF: 170

Average first/last/corresponding author IF: 6.1

Total citations (Scopus): 1000

H-index (Scopus): 18

ORCID ID: orcid.org/0000-0002-5949-3239SCOPUS Author ID: 7004469551ISI web of knowledge ResearcherID: F-3565-2015 

1. Rovida E, Digiacomo G, Tusa I, Bacci M, Cipolleschi MG, Dello Sbarba P. The cross talk between fibronectin-elicited signals and the receptor for the Colony-Stimulating Factor 1 (CSF-1R) sustains macrophage migration. 3rd Joint Meeting of Pathology and Laboratory Medicine. Montesilvano (PE), Italy, October 4th – 6th 2016. Am J Pathol. 186:s24.
2. Tusa I, Pandolfi S, Tubita A, Borgognoni L, Gagliardi S, Stecca B, Rovida E. The Extracellular signal-Regulated Kinase 5 is required for human melanoma cell growth. SipMet Young Investigator meeting. Alba (CN, Italy) 11-12 September 2015. Abstract book p9. https://drive.google.com/file/d/0B425tvuOafBSLU5iSnZhV2QzOU0/view.
3.  Digiacomo G, Ziche M, Dello Sbarba P, Donnini S, Rovida E. Prostaglandin e2 trans-activates the colonystimulating factor-1 (csf-1) receptor and synergizes with csf-1 in the induction of macrophage chemotaxis via the mitogen-activated protein kinase erk1/2. 56th Annual Meeting of the Italian Cancer Society, Ferarra, Italy. 11-13 September 2014. Abstract book D6:50.
4.  Tusa I, Cheloni G, Gray NS, Deng X, Dello Sbarba P, Rovida E. ERK5-inhibition as a novel approach to target CML stem cells. 55th Annual Meeting of the Italian Cancer Society, Catanzaro, 23-26 September, 2013. Abstract book E16:41.
5.  Rovida E, Di Maira G, Navari N, Rombouts K, Cannito S, Tusa S, Dello Sbarba P, Parola M, Marra F. ERK5 modulates the phenotype of hepatocellular carcinoma cells and tumor development. Biochemistry, Biology and pathology of MAP Kinases. 14-18 October 2012, Maale Hachamisha, Jerusalem Hills, Jerusalem, Israele. Abstract book p75.
6. Rovida E, Navari N, Cannito S, Giuntoli S, Di Maira G, Dello Sbarba P, Parola M, Marra F. ERK5 is overexpressed in liver injury and in hepatocellular carcinoma (HCC) and is modulated by soluble factors in HCC cells. 52° Annual Meeting of the Italian Society of Cancerology, Rome 4-7 October 2010. Abstract book p52.
7. Rovida E, Barbetti V, Morandi A, Dello Sbarba P. Expression and role in the proliferation of the Colony-Stimulating factor-1 Receptor in breast cancer cells. Società Italiana di Patologia XXX National Congress. Salerno, Italy, 14-17 October 2010. Am J Pathol.  177:s2-3.
8. Rovida E, Giuntoli S, Barbetti V, Dello Sbarba P. Role of ERK5 in the survival of myeloid leukemia cells in hypoxia. XI Congress of the Italian Society of Experimental Hematology. Turin, Italy, October 6-8, 2010. Haematoogica 95(s3):70.
9. Rovida E, Giuntoli S, Barbetti V, Dello Sbarba P. L’incubazione in ipossia profonda di cellule di leucemia mieloide induce apoptosi e proteolisi di ERK5. Corso sul “Ruolo dell’ipossia nella patogenesi dell’infiammazione e dei tumori”. Genova, Istituto G. Gaslini, 9 Maggio 2008.
10. Giuntoli S, Rovida E, Barbetti V, Morandi A, Tanturli M, Di Gesualdo F, Cipolleschi MG, Olivotto M, Dello Sbarba P. L’ipossia seleziona progenitori bcr/abl-indipendenti in una popolazione clonale di CML. Corso sul “Ruolo dell’ipossia nella patogenesi dell’infiammazione e dei tumori”. Genova, Istituto G. Gaslini, 9 Maggio 2008.
11. Barbetti V, Gozzini A, Rovida E, Dello Sbarba P, Mascagni P, Santini V. Specific degradation of the aml1-eto/corepressor complex by a novel “oral” hydroxamic acid derivative. IX Congress of the Italian Society of Experimental Hematology. Naples, Italy, September 20-22, 2006. haematologica/the hematology journal 2006; 91(s3):28.
12. Rovida E, Gozzini A, Barbetti V, Giuntoli S, Santini V, Dello Sbarba P. Le Mitogen-Activated Protein Kinases sono coinvolte nella proliferazione e nel differenziamento di una linea t(8;21) di leucemia mieloide acuta e sono modulate dal D1, un inibitore delle istone deacetilasi. XXVII Congresso Nazionale della Società Italiana di Patologia (SIP). Modena 20-23 Febbraio, 2005. Atti p122.
13. Barbetti V, Rovida E, Gozzini A,Giuntoli S, Santini V, Dello Sbarba P. Modificazioni epigenetiche in una linea t(8;21) di leucemia mieloide acuta causate dal D1. XXVII Congresso Nazionale della Società Italiana di Patologia (SIP). Modena 20-23 Febbraio, 2005. Atti p79.
14. Giuntoli S, Rovida E, Barbetti V, Gozzini A, Dello Sbarba P. L’incubazione in ipossia profonda di cellule di eritroleucemia murina di friend induce apoptosi e proteolisi di ERK5. XXVII Congresso Nazionale della Società Italiana di Patologia (SIP). Modena 20-23 Febbraio, 2005. Atti p179.
15. Giuntoli S, Rovida E, Barbetti V, Gozzini A, Dello Sbarba P. Incubation of murine erythroleukemia cells in severe hypoxia induces massive apoptosis paralleled by AKT and ERK5 cleavage. VIII Congress of the Italian Society of Experimental Hematology, Pavia, September 14-16, 2004. haematologica 2004 89(s6):28.
16. Rovida E, Lugli B, Dello Sbarba P. Macrophage Colony-Stimulating Factor–induced FAK activation is mediated by Src. 7^th Meeting of the European Hematology Association (EHA), Florence, Italy 6-9 June 2002. The Hematology Journal 2002 3(s1):362.
17. Gozzini A, Rovida E, Pratesi A, Dello Sbarba P, Rossi Ferrini P, Santini V. Acetylation induced by butyrates in patients with acute myeloid leukemia can lead to differentiation. VII Congress of the Italian Society of Experimental Hematology, Modena, September 15-17, 2002. Haematologica 2002 87(s9):30.

 POSTERS PRESENTED AT NATIONAL OR INTERNATIONAL MEETINGS 

1. Di Maira G, Gentilini A, Rovida E, Salvi M, Borgo C, Ottaviani D, Ruzzene M, Raggi C, Andersen JB, Marra F. The protein kinase CK2 contributes to the protumorigenic properties of cholangiocarcinoma cells. The Annual Meeting of the American Association for the Study of Liver Diseases: October 20-24 2017, Washington, DC. USA. Hepatology 2017 66(S1):975A.
2. Gentilini A, Caligiuri A, Di Maira G, Pastore M, Rovida E, Marra F. Extracellular signal-regulated kinase 5 (ERK5) regulates growth, migration and invasion of cholangiocarcinoma (CCA) cells. The Annual Meeting of the American Association for the Study of Liver Diseases: October 20-24 2017, Washington, DC. USA. Hepatology 2017 66(S1):989A.
3. Gentilini A, Caligiuri A, Di Maira G, Pastore M, Rovida E, Marra F. Extracellular signal-regulated kinase 5 (ERK5) regulates growth, migration and invasion of cholangiocarcinoma (CCA) cells. 51st Annual Meeting of the Italian Association for the Study of the Liver (A.I.S.F.) February 2018, Rome, Italy. Dig Liv Dis. 2018 50(s1):43.
4. Dello Sbarba P, Bono S, Cheloni G, Lulli M, Poteti M, Tusa I, Rovida E. The metabolically-modulated stem cell niche: an energy restriction model for leukaemia stem cell resistance to therapy. 3rd Joint Meeting of Pathology and Laboratory Medicine. Montesilvano (PE), Italy, October 4th – 6th 2016. Am J Pathol 2016 186:s20.
5. Tusa I, Cheloni G, Gray N, Gozzini A, DelloSbarba P, Rovida E. Inhibition of the ERK5 pathway as a novel approach to target human chronic myeloid leukemia stem cells. AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. Canc Res 2017 Volume 77, Issue 13 Supplement, pp. 3904.
6. Tusa I, Cheloni G, Gray NS, Gozzini A, Dello Sbarba P, Rovida E. MEK5-ERK5 inhibitors target chronic myeloid leukemia stem cells and in combination with imatinib reduce the expression of stem cell genes. 24^th Biennial Congress of the European Association for Cancer Research. 9-12 Luly 2016, Manchester UK. Eur J Canc 61(S1):s174.
7. Di Maira G, Gentilini A, Rovida E, Ottaviani D, Ruzzene M, Marra F. Role of the protein kinase ck2 in the biology of cholangiocarcinoma cells. 49th A.I.S.F. – Italian Association for the Study of the Liver – Annual Meeting 2016. Dig Liver Dis 2016 48(S1):e20.
8. Di Maira G, Gentilini A, Rovida E, Ottaviani D, Ruzzene M, Raggi C, Andersen JB, Marra F. Protein kinase CK2 modulates the oncogenic properties of cholangiocarcinoma cells. The Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016 November 11-15, 2016 - Boston, Massachusetts, USA. Hepatology 2016 63(S1):232A.
9. Morello E, Turato C, Cannito S, Ruvoletto M, Quarta S, Paternostro C, Novo E, Autelli R, Fasolato S, Tusa I, Rovida E, Colombatto S, Smedile A, Vitale A, Zanus G, Cillo U, Parola M, Pontisso P. Positive correlation of HIF2 alpha and serpinb3 in human hepatocellular carcinoma: selectivity and prognostic implications. Dig Liv Dis. 2015;47:E41-E42s1  Meeting Abstract: T-49.
10. Cannito S, Turato C, Morello E, Villano GM, Cillo U, Rovida E, Colombatto S, Martinez-chantar ML, Pontisso P, Parola M. SerpinB3 and HIF2a expression in liver cancer cells: Mechanisms and prognostic significance. EACR-AACR-SIC Special Conference. Florence, Italy. 20-23 June 2015; p227.
11. Pagliaro S, Rovida E, Dello Sbarba P, Castelo-Branco P, Moreira JN. Prostate cancer: Chemotherapy effects in cancer stem cells. EACR-AACR-SIC Special Conference. Florence, Italy. 20-23 June 2015; p247.
12. Cheloni G, Tanturli M, DeSouza N, Tusa I, Shan Y, Rovida E, Li S, Dello Sbarba P. Chronic myeloid leukemia stem cells are sensitive to the pharmacological inhibition of hypoxia-inducible factor-1a. EACR-AACR-SIC Special Conference. Florence, Italy. 20-23 June 2015; p441.
13. Tusa I, Pandolfi S, Borgognoni S, Gagliardi S, Stecca B, Rovida E. The Extracellular signal-regulated Kinase 5 is required for human melanoma cell growth. EACR-AACR-SIC Special Conference. Florence, Italy. 20-23 June 2015;p576.
14. Digiacomo G, Tusa I, Ziche M, Dello Sbarba P, Donnini S, Rovida E. PGE2 via EP4 receptor trans-activates the Colony-Stimulating Factor-1 (CSF-1) receptor and via the kinase ERK1/2 synergizes with CSF-1 in the induction of macrophage migration. EACR-AACR-SIC Special Conference. Florence, Italy. 20-23 June 2015;p584.
15. Tusa I, Cheloni G, Grey N, Deng X, Gozzini A, Rovida E, Dello Sbarba P. XMD8-92, an ERK5 inhibitor, in combination with imatinib, as a useful approach for CML treatment and prevention of relapse. EACR-AACR-SIC Special Conference. Florence, Italy. 20-23 June 2015;p295.
16. Digiacomo G, Ziche M, Dello Sbarba P, Donnini S, Rovida E. Prostaglandin E2 trans-activates the colonystimulating factor-1 (csf-1) receptor and synergizes with csf-1 in the induction of macrophage chemotaxis via the mitogen-activated protein kinase erk1/2. 56th Annual Meeting of the Italian Cancer Society, Ferarra, Italy. 11-13 September 2014. Abstract book D6:50.
17. Rovida E, Di Maira G, Cannito S, Tusa I, Paternostro C, Deng X, Dello Sbarba P, Gray NS, Parola M, Marra F. The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. Eur J Canc50, Suppl. 5 (2014) S189. 23rd Biennial Congress of the European Association for Cancer Research, 5–8 July 2014, Munich, German.
18. Digiacomo G, Ziche M, Dello Sbarba P, Donnini S, Rovida E. Prostaglandin E2 trans-activates the Colony-Stimulating Factor-1 (CSF-1) receptor and synergizes with CSF-1 in the induction of cell migration in macrophages via the mitogen-activated protein kinase ERK1/2. Eur J Canc50, Suppl. 5 (2014) S119. 23rd Biennial Congress of the European Association for Cancer Research, 5–8 July 2014, Munich, German.
19. Rovida E, Di Maira G, Tusa I, Cannito S, Paternostro C, Deng X, Gray N, Pandiella A, Dello Sbarba P, Parola M, Marra F. The mitogen-activated protein kinase erk5 as a new target for the treatment of hepatocellular carcinoma. 56th Annual Meeting of the Italian Cancer Society, Ferarra, Italy. 11-13 September 2014. Abstract book T14:125.
20. Tusa I, Cheloni G, Gray NS, Deng X, Dello Sbarba P, Rovida E. ERK5-inhibition as a novel approach to target CML stem cells. 55th Annual Meeting of the Italian Cancer Society, Catanzaro, 23-26 September, 2013. Abstract book E16:41.
21.  Rovida E, Di Maira G, Cannito S, Paternostro C, Dello Sbarba P, Parola M, Marra F. The mitogen-activated protein kinase erk5 regulates the development and growth of hepatocellular carcinoma. 55th Annual Meeting of the Italian Cancer Society, Catanzaro, 23-26 September, 2013. Abstract book T8:94.
22.  Tusa I, Cheloni G,Gray NS, Deng X, Rovida E, Dello Sbarba P. ERK5-inhibition as a novel approach to target CML stem cells. XII Congress of the Italian Society of Experimental Hematology, Roma, October 17-19, 2012. Haematologica, 2012; 97(s2):S73.
23.  Cheloni G, Tanturli M, Beneforti L, Rovida E, Dello Sbarba P. Gleevec-resistant CML stem and progenitor cells are sensitive to HIF-inhibiting drugs. XII Congress of the Italian Society of Experimental Hematology, Roma, October 17-19, 2012. Haematologica, 2012; 97(s2):S66-67.
24.  Rovida E, Tusa I, Cheloni G, Gray NS, Deng X, Dello Sbarba P. ERK5-inhibition as a novel approach to target chronic myeloid leukemia stem cells. Biochemistry, Biology and pathology of MAP Kinases. 14-18 October 2012, Maale Hachamisha, Jerusalem Hills, Jerusalem, Israele. Abstract book p107.
25. Rovida E, Barbetti V, Morandi A, Riverso M, Bessi S, Giannini A, Di Leo A, Dello Sbarba P. Identification in breast cancer cells of a novel mechanism of CSF-1R signalling which involves nuclear localization and binding to the promoter of genes involved in cell proliferation. IMPAKT Breast Cancer Conference 3-5 May 2012, Brussels, Belgium. Annals of Oncology 2012 23(2):40.
26. Rovida E, Barbetti V, Morandi A, Riverso M, Dello Sbarba P. Identification in breast cancer cells of a novel mechanism of CSF-1R signalling which involves its nuclear translocation and binding to the promoter of genes involved in cell proliferation. 53° Annual Meeting of the Italian Society of Cancerology, Torino, Italy, 19-22 October 2011. Abstract book p88.
27. Tanturli M, Giuntoli S, Barbetti V, Mazurier F, Rovida E, Dello Sbarba P. HIF suppression reveals a sensitivity of IM-resistant CML progenitor and stem cells to HIF-inhibiting drugs. 53° Annual Meeting of the Italian Society of Cancerology, Torino, Italy, 19-22 October 2011. Abstract book p34.
28. Di Maira G, Rovida E, Navari N, Rombouts K, Dello Sbarba P, Cannito S, Parola M, Marra F. Cytoskeletal rearrangement by the mitogen-activated protein kinase erk5 interferes with the motile and invasive phenotype of hepatocellular carcinoma cells. 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Germany, 2011 J Hepatol. 54:s87.
29. Di Maira G, Rovida E, Navari N, Rombouts K, Dello Sbarba P, Cannito S, Parola M, Marra F. Cytoskeletal rearrangement by the mitogen-activated protein kinase erk5 interferes with the motile and invasive phenotype of hepatocellular carcinoma cells. Digestive and liver disease 2011 43:S66.
30. Rovida E, Morandi A, Barbetti V, Dello Sbarba P. CSF-1 determines CSF-1R cytoplasmic nuclear shuttling in breast cancer cells. Società Italiana di Patologia XXX National Congress. Salerno, Italy, 14-17 October 2010. Am J Pathol.  177:s4.
31. Tanturli M, Giuntoli S, Rovida E, Barbetti V, Dello Sbarba P. Bortezomib specifically targets a subset of hypoxia-selected CML stem cells. Società Italiana di Patologia XXX National Congress. Salerno, Italy, 14-17 October 2010. Am J Pathol.  177:s29.
32. Giuntoli S, Tanturli M, Di Gesualdo F, Barbetti V, Rovida E, Dello Sbarba P. Glucose availability in hypoxia regulates the selection of CML progenitor subsets with different resistance to imatinib-mesylate. Società Italiana di Patologia XXX National Congress. Salerno, Italy, 14-17 October 2010. Am J Pathol.  177:s29-s30.
33. Tanturli M, Giuntoli S, Barbetti V, Rovida E, Dello Sbarba P. Bortezomib specifically targets a subset of hypoxia-selected CML stem cells. XI Congress of the Italian Society of Experimental Hematology. Turin, Italy, October 6-8, 2010. Haematoogica 95(s3):131.
34. Barbetti V, Gozzini A, Giuntoli S, Tanturli M, Santini V, Dello Sbarba P, Rovida E. Epigenetic modifications in a t(8;21) acute myeloid leukaemia cell line caused by administration of two HDAC inhibitors, VPA and SAHA. XI Congress of the Italian Society of Experimental Hematology. Turin, Italy, October 6-8, 2010. Haematoogica 95(s3):74.
35. Giuntoli S, Tanturli M, Di Gesualdo F, Barbetti V, Rovida E, Dello Sbarba P. Glucose availability in hypoxia regulates the selection of CML progenitor subsets with different resistance to imatinib-mesylate.XI Congress of the Italian Society of Experimental Hematology. Turin, Italy, October 6-8, 2010. Haematoogica 95(s3):131-132.
36. Barbetti V, Giuntoli S, Tanturli M, Rovida E, Dello Sbarba P. TRAIL is involved in hypoxia-induced apoptosis of acute myeloid leukemia t(8;21)-positive cells. XI Congress of the Italian Society of Experimental Hematology. Turin, Italy, October 6-8, 2010. Haematoogica 95(s3):147.
37. Rovida E, Morandi A, Barbetti V, Riverso M, Dello Sbarba P. CSF-1R elicits proliferative signals and undergoes cytoplasmic-nuclear shuttling in response to CSF-1 in breast cancer cells. 52° Annual Meeting of the Italian Society of Cancerology, Rome 4-7 October 2010. Abstract book p52.
38. Barbetti V, Giuntoli S, Tanturli M, Rovida E, Dello Sbarba P. TRAIL is involved in hypoxia-induced apoptosis of acute myeloid leukemia t(8;21)-positive cells. 52° Annual Meeting of the Italian Society of Cancerology, Rome 4-7 October 2010. Abstract book p78.
39. Barbetti V, Gozzini A, Giuntoli S, Tanturli M, Santini V, Dello Sbarba P, Rovida E. Epigenetic modifications in a t(8;21) acute myeloid leukaemia cell line caused by administration of two HDAC inhibitors, vpa and saha. 52° Annual Meeting of the Italian Society of Cancerology, Rome 4-7 October 2010. Abstract book p123.
40. Rovida E, Navari N, Cannito S, Dello Sbarba P, Parola M, Marra F. ERK5 is overexpressed in liver injury and in hepatocellular carcinoma (HCC) and is modulated by soluble factors in HCC cells. 45th Annual Meeting of the European-Association-for-the-Study-of-Liver-, APR 14-18, 2010 Vienna, AUSTRIA. J. Hepatol.  2010 52(s1):S347.
41. Rombouts K, Guerra CT, Caligiuri A, Bertolani C, Rovida E, Vizzutti F, Laffi G, Pinzani M, Marra F. The actin cytoskeleton as a novel target of AMP-activated protein kinase (AMPK) in hepatic stellate cells. 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, APR 22-26, 2009 Copenhagen, DENMARK. J. Hepatol.  2009 50(s1):S113.
42. Barbetti V, Gozzini A, Giuntoli S, Santini V, Dello Sbarba P, Rovida E. Epigenetic modifications in a t(8;21) acute myeloid leukaemia cell line caused by administration of the HDAC inhibitors. International Symposium on “Cancer genotypes and cancer phenotypes”. Firenze, Italy, 4-5 July, 2008.
43. Rovida E, Giuntoli S, Barbetti V, Dello Sbarba P. ERK5 forms are modulated by regulating phosphorylation and protein level in leukemia cells undergoing hypoxia-induced apoptosis. International Symposium on “Cancer genotypes and cancer phenotypes”. Firenze, Italy, 4-5 July, 2008.
44. Rovida E, Morandi A, Barbetti V, Di Leo A, Dello Sbarba P. The CSF1.R, product of the c-fms proto-oncogene, sustains the proliferation of breast cancer cells. International Symposium on “Cancer genotypes and cancer phenotypes”. Firenze, Italy, 4-5 July, 2008.
45. Rovida E, Navari N, Dello Sbarba P, Marra F. International Symposium on “Cancer genotypes and cancer phenotypes”. Firenze, Italy, 4-5 July, 2008.
46. Rovida E, Morandi A, Dello Sbarba. The CSF1.R, product of the c-fms proto-oncogene, sustains the proliferation of breast cancer cells. First intarnational conference “Translational Research in Oncology” Rimini, Italy,  May 14-16 2008.
47. Giuntoli S, Rovida E, Barbetti V, Cipolleschi MG, Olivotto M, Dello Sbarba P. Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations. IX Congress of the Società Italiana di Ematologia Sperimentale. Naples, Italy, September 20-22, 2006. haematologica/the hematology journal 2006; 91(s3):95.
48. Barbetti V, Giuntoli S, Dello Sbarba P, Rovida E. Erk5 mediates the macrophage colony-stimulating factor signalling in a Src-dependent and PKC-independent fashion. IX Congress of the Italian Society of Experimental Hematology. Naples, Italy, September 20-22, 2006. haematologica  2006; 91(s3):57.
49. Rovida E, Navari N, Dello Sbarba P, Marra F. Activation of ERK5, a member of the MAPK family, differentially regulates proliferation and migration of hepatic stellate cells. 41st annual meeting of the European Association for the study of the liver. April 26-30, 2006 Vienna, Austria. Journal of Hepatology 2006 44:s128.
50. Gozzini A, Barbetti V, Rovida E, Giuntoli S, Dello Sbarba P, Santini V. HDAC inhibitors in combination with hypomethylating agents induce specific chromatin modification and transcriptional activation in CBF/AML cells. 40th Congress of the Italian Society of Hematology, Bergamo, July 3-6, 2005. haematologica 2005 90(s3):78.
51. Dello Sbarba P.  Rovida E, Giuntoli S, Barbetti V, Olivotto M. ERK5 forms are modulated by regulating phosphorylation and protein level in leukemia cells undergoing hypoxia-induced apoptosis. 10th Congress of the European Hematology Association, Stockholm, Sweden, June 2-5, 2005. haematologica 2005 90(s2):194.
52. Dello Sbarba P, Giuntoli S, Rovida E, Barbetti V, Cipolleschi MG, Olivotto M. Hypoxia selects drug-insensitive progenitors within clonal leukaemia cell populations. 10th Congress of the European Hematology Association, Stockholm, Sweden, June 2-5, 2005. haematologica 2005 90(s2):283.
53. Rovida E, Giuntoli S, Barbetti V, Gozzini A, Dello Sbarba P. ERK5 forms are modulated by regulating phosphorylation and protein level in leukemia cells undergoing hypoxia-induced apoptosis. Second Erasmus Workshop on Molecular Therapeutics in Acute Leukemia. 7-8 October 2005, Rotterdam, The Netherlands, Atti p.117.
54. Santini V, Barbetti V, Gozzini A, Ferrari G, Dello Sbarba P, Rovida E. Short fatty acid-HDAC inhibitors induce specific chromatin modification and release gene silencing in CBF/AML cells. Second Erasmus Workshop on Molecular Therapeutics in Acute Leukemia. 7-8 October 2005, Rotterdam, The Netherlands, Atti p.133.
55. Barbetti V, Rovida E, Gozzini A, Giuntoli S, Santini V, Dello Sbarba P. Epigenetic modifications in a t(8;21) acute myeloid leukaemia cell line caused by administration of the HDAC inhibitor D1. VIII Congress of the Italian Society of Experimental Hematology, Pavia, September 14-16, 2004. haematologica 2004 89(s6):93.
56. Rovida E, Gozzini A, Barbetti V, Giuntoli S, Santini V, Dello Sbarba P. MAPKs are involved in the survival and differentiation of a t(8;21) acute myeloid leukemia cell line and are modulated by the HDAC inhibitor D1. VIII Congress of the Italian Society of Experimental Hematology, Pavia, September 14-16, 2004. haematologica 2004 89(s6):96.
57. Pacini S, Punzi T, Peruzzi B, Quagliata S, Dello Sbarba P, Rovida E, Gulisano M. Proliferation and in vitro angiogenesis in a human chronic myeloid leukemia cell line. LVIII Congresso della Società Italiana di Anatomia. Chieti, 17-19 September 2004. Italian Journal of Anatomy and Embryology 2004 109(s1):326.
58. Pacini S, Peruzzi B, Punzi T, Morucci G, Dello Sbarba P, Rovida E, Gulisano M. 1,25-dihydroxyvitamin D3 and ERK1/2 MAPK in a human chronic myeloid leukemia cell line. LVIII Congresso della Società Italiana di Anatomia. Chieti, 17-19 September 2004. Italian Journal of Anatomy and Embryology 2004 109(s1):324.
59. Rovida E, Gozzini A, Barbetti V, Santini V, Dello Sbarba P. The HDAC inhibitor D1 induces apoptosis and differentiation in a t(8;21) acute myeloid leukaemia cell line via MAPK modulation. First Erasmus Workshop on Molecular Therapeutics in Acute Leukemia. 12-13 September 2003, Rotterdam, The Netherlands. Atti p.127.
60. Peruzzi B, Gulisano M, Morucci G, Menchetti S, Dello Sbarba P, Rovida E, Ruggiero M, Paacini S. Effects of a human myeloid chronic leukemia cell line (K562) on in vivo angiogenesis. LVII Congresso della Società Italiana di Anatomia. Lipari, 14-18 September  2003. Italian Journal of Anatomy and Embryology 2003 108(s2):152.
61. Gozzini A, Rovida E, Pratesi A, Dello Sbarba P, Santini V. Monosaccharide butyrate derivative induces histone acetylation and granulocytic maturation in primary human AML blasts. 7^th Meeting of the European Hematology Association (EHA), Florence, Italy 6-9 June 2002. The Hematology Journal 2002 3(s1):190.
62. Rovida E, Lugli B, Dello Sbarba P. Characterization of signals linking the Macrophage Colony-Stimulating factor to the Focal adhesion Kinase. VII Congress of the Italian Society of Experimental Hematology, Modena, September 15-17, 2002. Haematologica2002 87(s9):119.
63. Rovida E, Lugli B, Dello Sbarba P. Caratterizzazione dei segnali che portano alla attivazione della Focal Adhesion Kinase da parte del Macrophage Colony-Stimulating Factor nei macrofagi. XXVI Congresso Nazionale della Società Italiana di Patologia (SIP). Catania, Italy 29 Settembre-2 Ottobre 2002. 0Atti p.13.
64. Rigacci S, Rovida E, Dello Sbarba P, Berti A. LMW-PTP associates and dephosphorylates FAK interfering with cell motility and spreading. XXXXVI Congresso della Società Italiana di Biochimica e Biologia Molecolare (SIB). Siena, Italy, 26-29 Settembre 2001. Italian Biochemical Society Transactions (IBST) 2001 17:255.
65. Santini V, Gozzini A, Rovida E, Dello Sbarba P, Rossi Ferrini P. V. Monosaccharide stable butyrate derivatives inhibit histone deacetylase, induce CEBPalpha expression and myeloid maturation in t(8;21) leukemia cells. 38th Congress of the Italian Society of Hematology, Florence, Italy, October 7-10, 2001.The Hematology Journal2001 86(s10):285.
66. Santini V, Gozzini A, Rovida E, Rossi Ferrini P. Butyrates recruit transcriptional repression and induce maturation of acute myeloid leukemia cells. 43rd Meeting of the American Society of Hematology, Orlado, Florida USA, December 7-11, 2001. Blood 2001 98(11):13.
67. Rovida E, Dello Sbarba P. La proliferazione autonoma di macrofagi murini indotta dal prodotto fel gene v-fes è mediata dall’attivazione costitutiva della via delle MAP-chinasi. XXV Congresso Nazionale della Società Italiana di Patologia (SIP). Bari, Italy 7-10 Giugno 2000. Atti p.14.
68. Rovida E, Marra F, Dello Sbarba P. Induced hyperphosphorylation of ERK. 26th Meeting of the federation of European Biochemical Society, Nice, France, June 19-24, 1999. Biochimie 1999 81:263.
69. Dello Sbarba P, Rovida E, Paccagnini A. Meccanismi di controllo dell’espressione e dell’attività del recettore per il Macrophage Colony-Stimulating Factor. XXIV Congresso Nazionale della Società Italiana di Patologia (SIP). Siena, Italy 24-27 Giugno 1998. Atti p.90.
70. Rovida E, Rigacci S,  Paccagnini A, Berti A, Dello Sbarba P. Ruolo della Fosfatasi a basso peso molecolare nella trasmissione dei segnali innescati dal Macrophage Colony-Stimulating Factor. XXIV Congresso Nazionale della Società Italiana di Patologia (SIP). Siena, Italy 24-27 Giugno 1998. Atti p.100.
71. Paccagnini A, Rovida E, Del Rosso M, Dello Sbarba P. Identificazione della proteasi effettrice della modulazione rapida del recettore per il Macrophage Colony-Stimulating Factor in corso di attivazione macrofagica. XXIV Congresso Nazionale della Società Italiana di Patologia (SIP). Siena, Italy 24-27 Giugno 1998. Atti p.260.
72. Rovida E, Rigacci S,  Paccagnini A, Berti A, Dello Sbarba P. Ruolo della Fosfatasi citosolica a basso peso molecolare nella modulazione della risposta al Macrophage Colony-Stimulating Factor. ABC convegno congiunto 1998 Montesilvano Lido, Italy 1-4 Ottobre 1998. Atti p.83.
73.  Dello Sbarba P, Cipolleschi MG, Rovida E, Olivotto M. La generazione di CFU-GM in vitro come indice del mantenimento delle cellule staminali ematopoietiche quiescenti in profonda ipossia. ABC convegno congiunto 1998 Montesilvano Lido, Italy 1-4 Ottobre 1998. Atti p.158.
74.  Dello Sbarba P, Rovida E, Caciagli B, Nencioni L, Labardi D, Savini L, Paccagnini A, Cipolleschi MG. La modulazione del recettore per il Macrophage Colony-Stimulating Factor in corso di attivazione macrofagica. XXIII Congresso Nazionale della Società Italiana di Patologia (SIP). Milano, Italy 23-26 Giugno 1996. Atti p.66.
75.  Dello Sbarba P, Nencioni L, Rovida E, Labardi D, Cipolleschi MG. Interleukin 2 down-modulates the expression of the Macrophage Colony-Stimulating Factor Receptor. Joint meeting SFI/GCI, Paris, France May 30-31 1994. Atti p.56.

FUNDINGS

2019-2024 (446.000 €/ 5 anni) “Dissecting the role of extracellular signal-regulated kinase 5 in cellular senescence and drug resistance in melanoma” finanziato dalla Associazione Italiana per la Ricerca sul Cancro. Call 2018 (IG-21349). Role on project: Principal investigator.

2018-2019 (20.000 €/ 1 anno) “La gestione del paziente con pemfigoide delle mucose: nuovi approcci per la diagnosi precoce e per la personalizzazione della terapia” granted by Fondazione Cassa di Risparmio di Firenze to Emiliano Antiga. Role on project: Unit leader.

2018 (3000 €/1 year) Granted by the Ministry of University and Research - FFARB 2018. Call 2017. Role on project: Principal Investigator.

2018 (1500 €/1 year) Identificazione di nuovi inibitori del recettore del Colony-Stimulating Factor-1 per ridurre la proliferazione di cellule di carcinoma della mammella del sottotipo triplo-negativo granted by the University of Florence (ex 60%). Call 2017. Role on project: Principal Investigator.

2016-2019 (251.000 € /3 anni) “Stroma-derived signals in the regulation of the biology of cholangiocarcinoma” granted by Associazione Italiana per la Ricerca sul Cancro to Fabio Marra. Call 2015. Role on project: co-investigator.

2017 (1250 €/1 year) Identificazione di nuovi inibitori del recettore del Colony-Stimulating Factor-1 per ridurre la proliferazione di cellule di carcinoma della mammella del sottotipo triplo-negativo granted by the University of Florence (ex 60%). Call 2016. Role on project: Principal Investigator.

2015-2018 (200000 €/ 3 years) “Role of cell-specific expression of ERK5 in the development of hepatocellular carcinoma associated with chronic liver injury” granted by Istituto Toscano Tumori to Fabio Marra. Call 2014. Role on project: co-investigator.

2015-2018 (203000 €/ 3 years) “Role of ERK5 in the selection of Chronic Myeloid Leukaemia cells in hypoxia in the design of strategies to suppress Minimal Residual Disease” ” granted by Istituto Toscano Tumori to Persio Dello Sbarba. Call 2014. Role on project: co-investigator.

2015-2018 (234000 €/ 3 years) “Targeting the Mitogen-Activated Protein Kinase ERK5 in human melanoma” granted by Associazione Italiana per la Ricerca sul Cancro. Call 2013 (IG-15282). Role on project: Principal investigator.

2013-2014 (60000 €/2 years) “Role of mitogen-activated protein kinase ERK5 in chronic liver injury and hepatocellular carcinoma” granted to Dr Fabio Marra by Fondazione Umberto Veronesi, Call 2012. Role on project: co-investigator.

2013-2015 (230.000 €/3 years) “The MAP kinase ERK5 as a novel target in hypoxia-resistant stem/progenitor cells of chronic myeloid leukaemia” granted to Dr Persio Dello Sbarba by Associazione Italiana per la Ricerca sul Cancro. Call 2012 (IG-13466). Role on project: co-investigator.

2012 (2000 €/1 year) “Evaluation of the effect of kinase inhibitors on the Colony-Stimulating Factor-1-dependent  proliferation in breast cancer cells” granted by the University of Florence (ex 60%). Call 2011. Role on project: Principal Investigator.

2011-2012 (22000 € /2 years) “Soppressione di BCR/Abl nelle Cellule Staminali Leucemiche (LSC) e loro resistenza all’Imatinib-mesilato come base per lo sviluppo di trattamenti LSC-specifici della Laucemia Mieloide Cronica” granted to Dr Persio Dello Sbarba by the Fondazione Bartolomei-Corsi. Call 2010. Role on project: co-investigator.

2011-2013 (€ 240.000/3 years) “Stem cell selection in severe hypoxia as a method to enhance recovery of transplantable normal stem cells and to isolate cancer stem cells to determine their drug sensitivity” granted by Regione Toscana – Programma per la Ricerca in materia di Salute - to Dr Persio Dello Sbarba. Call 2009. Role on project:co-investigator.

2010-2012 (180.000/3 years) “Role of the mitogen-activated protein kinase ERK5 in hepatocellular carcinoma” granted by Associazione Italiana per la Ricerca sul Cancro to Fabio Marra. Call 2009. Role on project: co-investigator.

2010-2011 (€ 100.000/2 years) “The mitogen-activated protein kinase ERK5 as a novel regulator of tumor-stroma interaction in hepatocellular carcinoma” granted by Istituto Toscano dei Tumori to Fabio Marra. Call 2008. Role on project: co-investigator.

2011-2012 (€ 133.870/2 years) “New therapeutic targets from the biology of the BCR-ABL oncogene” granted by Ministero della Salute Ricerca finalizzata – Regione Toscana RF-TOS-2008-1163728 to Persio Dello Sbarba. Call 2008. Role on project: co-investigator

2009-2011 (€ 150.000/3 years) “Characterisation and drug sensitivity of BCR/Abl-independent, Imatinib-resistant CML cells selected in hypoxia” granted by Associazione Italiana per la Ricerca sul Cancro (IG5220) to Persio Dello Sbarba. Call 2008. Role on project: co-investigator.

2009-2010 (€ 20.000/2 years) Granted by Associazione Italiana per la Lotta contro le Leucemie e i Linfomi – Prato to Dr Persio Dello Sbarba. Role on project: Co-investigator.

2008-2010 (€ 93.000/2 years) “Inhibition of BCR/Abl expression and induction of alternative anti-apoptotic mechanisms in hypoxia-adapted / Imatinib-insensitive CML stem cells” granted by the Istituto Toscano Tumori to Persio Dello Sbarba. Call 2007. Role on project: co-investigator.

2004-2006 (3 years) “Cancer stem cells: identification and fates inducible by environmental and epigenetic events” granted by Associazione Italiana per la Ricerca sul Cancro to Massimo Olivotto. Call 2003. Role on project: post-doctoral fellow.

2003-2005 (€ 88.000/2 years) “Role of hypoxia in the selection and maintenance of normal and neoplastic haematopoietic stem cells” granted by IstitutoSuperiore di Sanità (ISS), National Programme “Stem Cells” convenzione n° CS64 (Area Tematica 1A) to Persio DelloSbarba. Role on project: post-doctoral fellow.

2002-2004 (3 years) “An experimental contribution to the hypoxia-based therapy of cancer: biophysical and molecular studies”granted by Associazione Italiana per la Ricerca sul Cancro to Massimo Olivotto. Call 2001. Role on project: post-doctoral fellow.

2001 (1 year) “Ruolo dell’oncogene Fes nella adesione dei macrofagi” granted by the University of Florence- Young researcher project. Role on project: Principal Investigator.

1996-1998 (3 years) “Study of the integration of electric and biochemical signals in tumor cell commitment to differentiation: a contribution to a biological basis of the differentiation therapy of cancer” granted by Associazione Italiana per la Ricerca sul Cancro to Prof. Massimo Olivotto. Role on project: research fellow.

COLLABORATIONS

National collaborators

1. , Dipartimento di Scienze Biologiche e Cliniche, Università di Torino (Cannito S et al, Oncotarget 2015; Rovida et al, Gut 2015).
2. , Dipartimento di Medicina Sperimentale e Clinica Università di Firenze, (Rovida et al, Blood 2000; Rovida et, J Hepatol. 2008; Rovida et al, Gut 2015).

Prof. Valeria Santini, Unità Funzionale di Ematologia, Azienda Ospedaliro-Universitaria Careggi (AOUC) Firenze (Barbetti et al Epigenetics. 2013; Barbetti et al, Oncogene. 2008; Rovida et al, Br J Haematol. 2006; Gozzini, Rovida et al al, Cancer Res 2003).Dott.ssa Antonella Gozzini, Unità Funzionale di Ematologia, Azienda Ospedaliro-Universitaria Careggi (AOUC) Firenze (Del Poggetto et al, Cell cycle 2015; Barbetti et al Epigenetics. 2013; Barbetti et al, Oncogene. 2008; Giuntoli et al, Stem Cells 2007; Rovida et al, Br J Haematol 2006; Gozzini, Rovida E et al, canc Res, 2003).Dott.ssa Barbara Stecca, Istituto Toscano Tumori, Firenze, (Cipolleschi et al, Cell Cycle 2014; Marzi et al,Cell Cycle. 2013; Rovida and Stecca,Semin Cancer Biol. 2015; Tusa et al, Oncogene 2018).

Prof Marina Ziche, Dipartimento di Scienze della Vita, Università di Siena (Digiacomo et al, FASEB J 2015)

International collaborators

1. , Center for Molecular Biology, Max F. Perutz Laboratories, University of Vienna, Vienna, Austria (Rovida et al, Oncogene 2002; Rovida et al, Blood 2000).

Dr Jacques Peschon, Seattle Biomedical Research Institute, Seattle (Rovida et al, 2001).

Dr Michael Lübbert, Division of Hematology/Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, D-79106 Freiburg, Germany (Barbetti et al, Oncogene 2008).

Dr Atanasio Pandiella, Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain (Rovida et al, Gut 2015).

1. , Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA (Rovida et al, Gut 2015; Tusa et al, Oncogene 2018).

Dr Shaoguang Li, Aaron Lazare Medical Research Building (LRB), UMass Medical School, Worcester, MA, USA (Cheloni et al, Blood 2017).

AWARDS AND HONOURS

2017-present       EACR Ambassador

2016                    Habilitation - Associate Professor of General Pathology (Abilitazione Scientifica Nazionale II fascia SETTORE CONCORSUALE 06/A2 -PATOLOGIA GENERALE E PATOLOGIA CLINICA)

Winner of the following fellowships

2007                    (2 years) fellowship funded by the Fondazione Italiana per la Ricerca sul Cancro (FIRC).

2001                    (3 years) fellowship funded by the Fondazione Italiana per la Ricerca sul Cancro (FIRC).

Invited speaker

2017, September 28^th “Olistic approach of chronic myeloid leukemia”, supported by Accademia Nazionale di Medicina. Florence, Italy. Molecular pathways beyond BCR/ABL in chronic myeloid leukemia stem cell.

 2014, November 13^th Istituto Toscano Tumori, Firenze, Italy. Colony-Stimulating Factor-1 Receptor and Extracellular signal-Regulated Kinase 5 in cancer.

2013, April 8^th      Aaron Lazare Medical Research Building (LRB), UMass Medical School, Worcester, MA, USA. The MAP kinase ERK5 as a novel target in hypoxia-resistant stem/progenitor cells of chronic myeloid leukaemia.

2010, June 25^th    Albert Einstein College of Medicine, Bronx, NY, USA. Intra-cellular localization of the Colony-Stimulating Factor-1 Receptor: possible role in breast cancer pathogenesis?

2010, May 4^th      Expression and intra-cellular localization of the macrophage Colony-Stimulating Factor Receptor in breast cancer cells, Denothe, University of Florence, Italy.

Member of the following scientific societies (past and/or present)

2000-present       Italian Society of Pathology and Translational Medicine (SIPMET)

2006-present       Italian Society of Experimental Hematology (SIES)

2012-present       Italian Cancer Society (SIC)

2013-present       European Association for Cancer Research (EACR)

2013                    American Association for Cancer Reserch (AACR).

Grant reviewer for international funding agencies

2018                    North West Cancer Research (http://www.nwcr.org/)

2018                    Università di Verona, Bando di Ateneo per la Ricerca di Base.

2015                    Etablissement Français du Sang / France National Blood Service (EFS).

2013-present       The Health and Medical Research Fund of the Food and Health Bureau under The Government of the Hong Kong SAR.

Hosting of visiting Professor

March 2017         Prof. Atanasio Pandiella from “Centro de Investigación del Cáncer (Universidad de Salamanca-CSIC)”, Salamanca, Spain.

Editorial board member

2016-present Review Editor of Signaling, part of the journal Frontiers in Cell and Developmental Biology.

Referee for scientific journals

European Respiratory Journal

Cancers

Oncogenesis

Frontiers in Oncology

Frontiers in Cell and Developmental Biology

Biochemistry & Cell Biology

International Journal of Molecular Sciences

The International Journal of Biochemistry & Cell Biology

Cellular Signalling

Liver International

Stem Cells International

PloS One

Current Medicinal Chemistry

Arzneimittelforschung/Drug Research

Leukaemia Research

Journal of Inflammation

Biochemical Pharmacology

The British Journal of Haematology

MAIN SCIENTIFIC ACHIEVEMENTS

1. The hematopoietic colony-stimulating factor 1 (hCSF-1) is essential for innate and adaptive immunity against viral and microbial infections and cancer. E.R. identified two novel cytokines as responsible for CSF-1R down-modulation in the course of macrophage activation (Cytokines 1996, J Leukoc Biol 1996), and eventually clarified the relative mechanism, identifying TNF alpha converting enzyme (TACE, also called ADAM17) as the protease responsible for the cleavage of CSF-1R (J Immunol 2001; Biol Chem 2002). E.R. established the central role of ERK1/2 activation, and the importance of CSF-1R in its fine tuning, in macrophage proliferation (Blood 2000, Oncogene 2002). In collaboration with Prof. Andrea Berti, Department of Biochemical Sciences, University of Florence, E.R. identified CSF-1R and FAK as two novel targets of the Low molecular weight protein tyrosine phosphatase (LMW-PTP) (Biochem Biophys Res Commun 1998, J Biol Chem 2002, FEBS Lett). More recently, E.R. identified two novel molecules downstream CSF-1R signalling, namely the Focal adhesion kinase (FAK) and the MAPK ERK5 (Biol Chem 2005, J Immunol 2008), which are important for CSF1-induced adhesion and proliferation, respectively. The importance of ERK5 in cell proliferation was also established in stellate hepatic cells, in collaboration with Prof. Fabio Marra, Department of Internal Medicine, University of Florence (J Hepatol 2008). Furthermore, E.R. identified CSF-1R as a crucial signal controlling the proliferation of breast cancer cells via ERK1/2 activation (PLoSOne, 2011a). ER also identified a new mechanism of action of CSF-1R which involves its translocation to the nucleus and binding to the the promoter of proliferation-related genes in breast cancer cells (Oncogene 2013)

2. Another field of interest was the regulatory effects of hypoxia on normal hematopoietic stem cells (Leukemia 2000, Br J Haematol 2000). Later, ER extended to myeloid leukemia stem cells (LSC) the liability to selection under hypoxia (Stem Cells 2007). A crucial finding was that hypoxia suppresses the BCR/Abl oncogenic protein, so that stem cells of Chronic Myeloid Leukaemia (CML) are completely insensitive to the BCR/Abl inhibitor imatinib-mesylate (IM), the main drug currently used for CML therapy (Leukemia 2006). These studies provided a necessary background to undertake the search on drugs endowed with a mechanism of action different from that of IM and capable to target BCR/Abl(protein)-negative stem cells. In this context, the proteasome-inhibitor Bortezomib, currently subjected to trials for advanced CML therapy, was found to be actually unable to target CML stem cells (PlosOne, 2011b). The effects of hypoxic versus ischemic environment with respect to stem cells were also investigated and molecular mechanisms responsible for cancer maintenance were identified (Cell cycle 2013; , Haematologica 2011). E.R. also studied the effects of histone-deacetylase inhibitors (HDACi) in the treatment of acute leukaemia. In collaboration with Prof Valeria Santini, Division of Hematology, University of Florence, E.R. published novel aspects of HDACi action. In particular, HDACi as single drug were found to induce myeloid maturation and massive apoptosis in acute myeloid leukemia (AML) cells (Canc Res 2003). The anti-leukemic effect of HDACi was demonstrated to be further increased by combined administration of MAPK inhibitors (Br J Haematol 2006). Moreover, ER demonstrated that a specific subtype of AML, namely that characterized by the t(8;21) translocation, is specifically sensitive to HDACi (Oncogene 2008). In the same area we found that different HDACi induce peculiar pattern of Histone acetylation and biological responses (Epigenetics 2013). We also identified a new mechanism of action of AML1/ETO oncogenic protein in the prevention of apoptosis that involves blockade of TRAIL expression (Cell Death Dis 2013).

SELF EVALUATION

TEACHING

2016 Habilitation - Associate Professor of General Pathology (Abilitazione Scientifica Nazionale II fascia SETTORE CONCORSUALE 06/A2 -PATOLOGIA GENERALE E PATOLOGIA CLINICA)

2016-present Advisory Board Member – Doctorate in genetics, oncology and clinical medicine (GenOMeC), University of Siena

2016-present   teaching of General and Oral Cavity Oncology, Degree of Dental Medicine and Prosthetics Degree, School of Human Health Sciences, Univeristy of Florence, Italy.

2016-present teaching of Immunology, Degree of Orthopaedics Techniques, School of Human Health Sciences, Univeristy of Florence, Italy.

2016-present teaching of cytopatology, Degree of Biomedical Laboratory Technologies, School of Human Health Sciences, Univeristy of Florence, Italy.

2015-present Supervisor of 2 PhD students

2005-present teaching of Histopathology, Degree in Medicine and Surgery, School of Medicine, School of Human Health Sciences, , Univeristy of Florence, Italy.

2003-present Supervisor of 15 First Level Degree studens (School of Medicine, Degree in Biotechnologies, Curriculum: Medical-Pharmaceutical)

2003 ufficially appointed as an expert in General Pathology, Immunology and Immunoematology by the School of Medicine at the University of Florence.

2002-present Supervisor of 20 Master Degree students (School of Medicine, Degree in Medical and Pharmaceutical Biotechnology; School of Mathematical, Physical and Natural Sciences, Degree in Biology)

2001- teaching of General Pathology and Immunology at the School of Medicine (Midwifery, Nursing, Physiotherapy, Biotechnologies Curriculum: Medical-Pharmaceutical).

Identification of the molecular mechanisms responsible for sustained cell proliferation and reduced sensitivity to antiproliferative factors in tumor cells, with particular attention to the involvement in the aforementioned biological processes of the Colony-Stimulating Factor-1 Receptor (CSF-1R) and Mitogen-Activated Protein Kinases (MAPK), ERK5 in particular.

Identification of mechanisms of resistance to molecular therapies directed to MAPK in solid tumors and to BCR/ABL in chronic myeloid leukemia.